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Objectives: A series of N-(5,6-dimethyl-1H-benzimida-
zol-2-yl) substituted carboxamide was synthesized using
the reaction of 2-amino-5,6-dimethyl-1H-benzimidazole-
withvarious bioactive aromatic heterocyclic carboxylic
acids and fatty acids with several catalysts.
Methods: The structures of the synthesized compounds
were confirmed using 1H and 13C nuclear magnetic
resonance (NMR) and mass spectroscopic methods. The
title compounds were screened for antimicrobial and
antioxidant activity.
Results: Compounds 3e, 3f, 3g, 3h, 3j and 3l exhibit
promising antimicrobial activity against the tested micro-
organisms with minimal inhibitory concentration (MIC)
values of 250e750 mg/ml. Compounds 3g, 3h and 3j show
prominent radical scavenging and ferrous ion chelating
activity, with IC50 values of 49.00 65 to 57.18 89 mg/ml.
Conclusion: All of the synthesized compounds show good
antimicrobial and antioxidant activities. This study reveals
that the incorporation of a heterocyclic ring and open-chain
counterparts at the second position of the benzimidazole
ring yields more potent biologically active compounds.
Keywords: 2-Amino-5,6-dimethyl-1H-benzimidazole; Antimi-
crobial;Antioxidant; Ferrous ion chelating;Radical scavenging
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Over the past few decades, many existing antimicrobial
synthetic drugs have become less effective against certain
diseases because many of these drugs produce toxic reactions
leading to the emergence of drug-resistant bacteria and
fungal strains. During the biological redox process, some
biological imbalances cause the over-production of reactive
oxygen species, which degrade cellular components by
extracting electrons from them to attain stability, eventually
causing cellular dysfunction and cell death.
In pharmaceutical industries, benzimidazole acts as a
pharmacophore ring to synthesize biologically active moi-
eties. Some benzimidazole derivatives were proven to be
associated with antibacterial, antifungal, antiviral, antioxi-
dant, antihelmintic, anti-inflammatory, anticancer, antihis-
taminic, anti-anxiety and antihypertensive activity.1,2
In recent years, efficient and selective catalytic methods
for amide formation have satisfied the increasing demand for
green chemistry procedures. A number of catalysts are
available for amide bond formation, such as PS-EDC, PS-
DCC, PS-TBTU and TAPC.3e6 In this article, we report a
series of N-(5,6-dimethyl-1H-benzimidazol-2-yl)-substituted
carboxamide derivatives using HATU [(1-[Bis(dimethyla-
mino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-
xidhexafluorophosphate)] and EDC.HCl [(1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide)] as catalysts and
screened their antimicrobial and antioxidant activities.
Materials and Methods
Chemistry
Synthesis of 5,6-dimethyl-1H-benzimidazol-2-amine (2)
5,6-dimethyl-1H-benzimidazol-2-amine (2) was synthe-
sized using a previously reported procedure.7 Compound
formation was confirmed by comparing its melting point
with the literature value (mp: 225e227 C).
General synthesis procedure of compounds 3(aep)
Coupling reaction catalysed by EDC.HCl
The reaction mixture, which contained compound 2
(0.0062 mol), substituted carboxylic acids (0.0086 mmol),
the catalyst EDC.HCl (0.0248 mol) and 4-
dimethylaminopyridine in 5 mL of dichloromethane, was
stirred for 6e10 h. The completion of the reaction was
monitored using TLC. After the reaction completed, the re-
action mixture was cooled and poured into crushed ice; the
precipitated product was filtered, dried, and recrystallized
from methanol. The product was further purified using silica
gel column chromatography.
Coupling reaction catalysed by HATU
The reaction mixture, which contained compound 2
(0.0062 mol), substituted carboxylic acids (0.0074 mmol),
catalyst HATU (0.0124 mol) and N,N-
diisopropylethylamine (0.0077 mol) in 5 mL of dichloro-
methane, was stirred for 3e6 h. After the reaction completed,
the mixture was cooled and poured into crushed ice; the
precipitated product was filtered, dried, and recrystallizedfrom methanol. The product was further purified using silica
gel column chromatography with Ethyl acetate: pet ether
(1:5) as the mobile phase. 1HNMR and 13CNMR spectra
were recorded on a Bruker 400 MHz spectrometer. LC-MS
was obtained using a C-18 column on Shimadzu, LCMS
2010A, Japan.
N-(5,6-dimethyl-1H-benzimidazol-2-yl)benzamide (3a). Brown
solid: mol. formula: C16H15N3O; mp: 178e180
C; 1H NMR
(400 MHz, DMSO, d ppm): 8.11 (s, 1H, amide), 6.86 (s, 2H,
benzimidazole), 7.40 (d, J¼ 8 Hz, 2H, AreH), 7.60e7.54 (m,
3H, AreH), 6.04 (s, imidazole-H), 2.31 (s, 6H, 2  CH3);
13CNMR (125 MHz, CDCl3, d ppm): 172.55 (C]O amide),
167.99, 147.62, 132.76, 131.62, 129.49, 128.75, 128.14,
127.68, 96.15, 20.26 (methyl); MS (LCMS): m/z 265 [Mþ].
N-(5,6-dimethyl-1H-benzimidazol-2-yl)-2,4-dimethylbenzamide
(3b). Brown solid; mol. formula: C18H19N3O; mp: 164e
165 C; 1H NMR (400 MHz, DMSO, d ppm): 8.01 (s, 1H,
amide),7.67(d, 1H, AreH), 7.43 (s, 2H, AreCH), 7.21 (m,
2H, AreH), 5.82 (s, 1H, imidazole-H), 2.41 (s, 3H), 2.38 (s,
3H), 2.21 (s, 6H, 2  CH3); 13CNMR (125 MHz, CDCl3,
d ppm): 169.76 (C]O amide), 148.24, 135.87, 135.24, 135.11,
127.01, 129.24, 126.14, 126.04, 125.68, 22.14, 21.57, 19.79;
MS (LCMS): m/z 293[Mþ].
N-(5,6-dimethyl-1H-benzimidazol-2-yl)-2-methoxybenzamide (3c).
Brownish yellow solid; mol. formula: C17H17N2O2; mp:
169e172 C; 1H NMR (400 MHz, CDCl3, d, ppm): 8.18 (s,
1H, amide), 7.88e7.86 (d, J ¼ 6.8 Hz, 2H AreH), 7.15 (d,
J ¼ 12 Hz, 2H AreH), 7.10e7.06 (m, 2H, AreH), 5.62 (s,
1H, imidazole-H), 4.04 (s, 3H, OCH3), 2.27 (s, 6H, 2 CH3);
13CNMR (125 MHz, CDCl3, d ppm): 164.13 (C]O amide),
157.79, 146.19, 134.41, 132.48, 132.32, 131.46, 130.78,
127.75, 121.54, 121.02, 119.70, 111.83, 96.15, 56.15, 20.33;
MS (LCMS): m/z 296 [Mþ].
N-(5,6-dimethyl-1H-benzimidazol-2-yl)-2-(2-methoxyphenyl)acet-
amide (3d). Brown solid; mol. formula: C18H19N3O2; mp:
154e156 C; 1H NMR (400 MHz, CDCl3, d, ppm): 8.06 (s,
1H, amide), 7.79 (d, J ¼ 7.6 Hz, 2H, AreH), 7.02e6.92 (m,
4H, AreH), 5.71 (s, 1H, imidazole-H), 3.92 (s, 3H, OCH3),
3.62 (s, 2H), 2.14 (s, 6H, 2  CH3); 13CNMR (125 MHz,
CDCl3, d ppm): 165.97 (C]O amide), 156.95, 143.97,
132.87, 128.41, 128.21, 126.71, 124.01, 119.64, 112.32,
112.65, 53.27, 28.57, 20.31; MS (LCMS): m/z 309 [Mþ].
2,4-Dichloro-N-(5,6-dimethyl-1H-benzimidazol-2-yl)benzamide
(3e). Yellow solid; mol. formula: C16H13Cl2N3O; mp: 189e
192 C; 1H NMR (400 MHz, DMSO, d ppm): 8.14 (s, 1H,
amide), 7.61 (d, J ¼ 8.8 Hz, 2H AreH), 7.41e7.21 (m, 3H,
AreH), 6.4 (s, 1H, imidazole-H), 2.02 (s, 6H, 2  CH3);
13CNMR (125 MHz, CDCl3, d ppm): 162.81 (C]O amide),
154.91, 136.14, 133.81, 131.71, 128.57, 128.36, 128.24,
128.15, 127.40, 125.13, 113.34, 20.45; MS (LCMS): m/z
Calculated: 335 [Mþ] and 337 [Mþ2].
N-(5,6-dimethyl-1H-benzimidazol-2-yl)-2,4-dinitrobenzamide (3f).
Brownish yellow solid; mol. formula: C16H13N5O5; mp:
184e186 C; 1H NMR (400 MHz, DMSO, d ppm): 9.54 (s,
1H, AreH), 8.71 (d, J ¼ 8 Hz, 2H, AreH), 8.41 (s, 1H,
amide), 7.57 (s, 2H, AreH), 5.62 (s, 1H, imidazole-H) 2.5 (s,
Synthesis of 2-amino-5,6-dimethyl-1H-benzimidazole derivatives4206H, 2  CH3); 13CNMR (125 MHz, CDCl3, d ppm): 167.86
(C]O amide), 150.71, 146.12, 145.91, 133.81, 133.21,
127.37, 125.30, 116.54, 113.34, 19.78; MS (LCMS): m/z 355
[Mþ].
N-(5,6-dimethyl-1H-benzimidazol-2-yl)-1H-1,2,4-triazole-3-
carboxamide (3g). Brown solid; mol. formula: C12H12N6O;
mp: 192e193 C; 1HNMR (400MHz, DMSO, d ppm): 12.81
(s, 1H, triazole), 8.73 (s, 1H, triazole-H), 8.04 (s, 1H, amide),
7.57 (d, J ¼ 6.3, 2H, AreH), 6.30 (s, 1H, imidazole-H) 2.41
(s, 6H, 2  CH3); 13CNMR (125 MHz, CDCl3, d ppm):
160.35(C]O amide),156.01, 151.14, 145.97, 133.81, 133.45,
133.14, 130.14, 113.24, 19.87; MS (LCMS): m/z 256 [Mþ].
N-(5,6-Dimethyl-1H-benzimidazol-2-yl)-5-methyl-1,2-oxazole-3-
carboxamide (3h). Brown solid; mol. formula: C14H14N4O2;
mp: 195e196 C; 1H NMR (400 MHz, DMSO, d ppm): 8.11
(s, 1H, amide), 7.21 (d, J ¼ 8.0, 2H, AreH), 6.82 (s, 1H
oxazole-H), 5.31 (s, 1H, imidazole-H),2.81 (s, 3H, CH3), 2.32
(s, 6H, 2  CH3); 13CNMR (125 MHz, CDCl3, d ppm):
167.85 (CeO), 160.57(C]O amide), 147.31, 133.21, 129.34,
112.47, 27,87, 10,68; MS (LCMS): m/z 270 [Mþ].
N-(5,6-dimethyl-1H-benzimidazol-2-yl)pyrazine-2-carboxamide
(3i). Brown solid; mol. formula: C14H13N5O; mp: 204e
206 C; 1H NMR (400 MHz, CDCl3, d ppm): 9.21e8.91 (m,
3H, pyrazine), 8.11 (s, 1H, amide), 7.51e7.49 (d, J ¼ 7.1 Hz,
2H AreH), 5.84 (s, 1H, imidazole-H), 2.24 (s, 6H, 2  CH3);
13CNMR (125 MHz, CDCl3, d ppm): 160.26 (C]O amide),
146.94, 145.24, 143.42, 142.74, 140.83, 133.87, 128.21,
112.53, 20.81; MS (LCMS): m/z 267 [Mþ].
N-(5,6-dimethyl-1H-benzimidazol-2-yl)-1-methyl-1H-benzotriazole-
6-carboxamide (3j). Light yellow solid; mol. formula:
C17H16N6O; mp: 210e211
C; 1HNMR (400MHz, CDCl3, d,
ppm): 8.64e8.42 (m, 3H, benzotriazole-H), 8.24 (s, 1H, amide),
7.24 (d, J¼ 6.8 Hz, 2HAreH), 5.91 (s, 1H, imidazole-H), 3.92
(s, 3H, N-CH3), 2.24 (s, 6H, 2  CH3); 13CNMR (125 MHz,
CDCl3, d ppm): 162.21 (C]O amide), 146.21, 143.57, 133.68,
132.71, 130.64, 128.64, 128.10, 125.34, 113.27, 111.31, 40.02,
19.56; MS (LCMS): m/z 320 [Mþ].
N-(5,6-dimethyl-1H-benzimidazol-2-yl)-4-(1H-pyrazol-1-yl)benza-
mide (3k). Pale yellow solid; mol. Formula: C19H17N5O; mp:
203e205 C; 1H NMR (400 MHz, CDCl3, d, ppm): 8.39 (s,
1H, amide-H), 8.26 (d, J ¼ 8.8 Hz, 2H, AreH), 7.86 (s, 2H,
AreH), 7.80 (d, J¼ 8.8 Hz, 2H, AreH), 7.20 (s, 2H, AreH),
7.14 (s, 1H, AreH), 2.27 (s, 6H, 2  CH3); 13CNMR
(125 MHz, CDCl3, d ppm): 165.23 (C]O amide), 135.43,
131.83, 130.52, 120.90, 117.77, 99.99, 77.27, 29.70, 20.21; MS
(LCMS): m/z 331 [Mþ].
N-(5,6-dimethyl-1H-benzimidazol-2-yl)-1-benzofuran-2-
carboxamide (3l). Brown solid; mol. formula: C18H15N3O2;
mp: 174e176 C; 1H NMR (400 MHz, CDCl3, d, ppm): 8.14
(s, 1H, amide-H), 7.81 (s, 1H, AreH), 7.61 (m, 2H, AreH),
7.58 (d, J ¼ 8.8 Hz, 2H, AreH), 7.42 (m, 2H, AreH), 6.4 (s,
1H, imidazole-H), 2.31 (s, 6H, 2  CH3); 13CNMR
(125 MHz, CDCl3, d ppm): 164.71 (C]O amide), 160.48,
152.80, 149.96, 138.87, 133.51, 132.64, 126.58, 123.01,
117.37, 113.01, 20.97; MS (LCMS): m/z 305 [Mþ].N-(5,6-dimethyl-1H-benzimidazol-2-yl)-4,4,4-trifluorobutanamide
(3m). Brown solid; mol. formula: C13H14F3N3O; mp: 124e
126 C; 1H NMR (400 MHz, CDCl3, d, ppm): 7.19 (s, 1H,
amide-H), 6.90 (s, 2H, AreH), 6.3 (s, 1H, imidazole-H),
2.71(t, 2H), 2.24 (s, 3H, CH3), 2.19 (s, 3H, CH3);
13CNMR
(125 MHz, CDCl3, d ppm): 156.81 (C]O amide), 136.85,
135.19, 133.86, 116.39, 99.99, 81.28, 53.18, 23.80; MS
(LCMS): m/z 285 [Mþ].
2,2,2-Trichloro-N-(5,6-dimethyl-1H-benzimidazol-2-yl)acetamide
(3n). Brown solid; mol. formula: C11H10Cl3N3O; mp: 118e
121 C; 1H NMR (400 MHz, CDCl3, d, ppm): 7.51 (s, 1H,
amide-H), 7.15 (s, 2H,AreH), 6.4 (s, 1H, imidazole-H), 2.28 (s,
6H, 2  CH3); 13CNMR (125 MHz, CDCl3, d ppm): 158.36
(C]O amide), 149.91, 137.82, 137.42, 133.42, 117.84, 95.12,
21.46;MS (LCMS):m/z 307 [Mþ], 309 [Mþ2] and 311 [Mþ4].
N-(5,6-dimethyl-1H-benzimidazol-2-yl)stearamide (3o). Brown
solid; mol. formula: C27H45N3O; mp: 142e146
C; 1H NMR
(400MHz, CDCl3, d, ppm): 7.87 (s, 1H, amide-H), 7.21 (s, 2H,
AreH), 6.10 (s, 1H, imidazole-H), 2.41 (s, 6H, 2  CH3), 2.34
(m, 2H), 1.73 (m, 2H), 1.31 (m, 28H), 1.1 (m, 3H); 13CNMR
(125 MHz, CDCl3, d ppm): 161.34 (C]O amide), 150.92,
136.84, 132.41, 132.28, 130.81, 117,41, 38.18, 33.47, 31.28,
31.01, 28,74, 24.91, 20.67, 16.47; MS (LCMS): m/z 427 [Mþ].
N-(5,6-dimethyl-1H-benzimidazol-2-yl)tetradecanamide (3p). Brown
solid; mol. formula: C23H37N3O; mp: 154e156
C; 1H NMR
(400MHz, CDCl3, d, ppm): 7.91 (s, 1H, amide-H), 7.43 (s, 2H,
AreH), 6.31 (s, 1H, imidazole-H), 2.31 (s, 6H, 2  CH3), 2.20
(m, 2H), 1.82 (m, 2H), 1.34 (m, 20H), 0.98 (m, 3H); 13CNMR
(125 MHz, CDCl3, d ppm): 164.12 (C]O amide), 149.97,
136.24, 132.41, 117.34, 38.54, 33.47, 31.01, 30.47, 29.78, 27.64,
24.54, 20.84, 18.64; MS (LCMS): m/z 371 [Mþ].
Pharmacology
In vitro antibacterial and antifungal activity
The antimicrobial activities of the synthesized com-
pounds were examined using the agar well diffusion
method.8 All bacterial strains were maintained in a nutrient
agar medium at 37 C, and the fungal strains were
maintained in potato dextrose agar at 25 C. The test
compounds were dissolved in DMSO to obtain a
concentration of 1000 mg/mL, and 100 mL of this sample
was directly loaded into the wells of agar plates. Plates
that were inoculated with the bacteria were incubated at
37 C for 24 h, and the fungal culture was incubated at
25 C for 72 h. All determinations were performed in
triplicate. Ciprofloxacin (500 mg/mL) and fluconazole
(500 mg/mL) were used as standard drugs for the
antibacterial and antifungal activities, respectively.
Determination of the Minimum Inhibitory Concentration
(MIC) was performed using the serial broth-dilution
method at different concentrations of 250, 500, 750 and
1000 mg/mL. After the incubation period, the minimum
inhibition zone, where microorganism growth was inhibi-
ted, was measured in mm.
In silico molecular docking studies
The structure of glucosamine-6-phosphate synthase
(GlcN-6-P synthase) protein was obtained from the
A.S. M. et al. 421protein data bank (PDB) with accession number
“2VF5.pdb”.9 In the present study, the active site was
selected based on the amino acid residues, which are
involved in binding GlcN-6-P synthase in the complex.
The grid was centred at the region that included all 10
amino acid residues (Ala602, Val399, Ala400, Gly301,
Thr302, Ser303, Cys300, Gln348, Ser349, Thr352, Ser347,
and Lys603) that surround the active site with either hy-
drophobic interactions or hydrogen bonds. All Auto Dock
docking runs were performed using a Corei7 Intel pro-
cessor CPU with 8 GB DDR3l RAM. AutoDockVina was
compiled and run in a Windows 8.0 professional operating
system. LigPlotþ and PyMol were used to deduce the
pictorial representation of the interaction between the li-
gands and the target protein.
Antioxidant activity
1,1-Diphenyl-2-picrylhydrazyl (DPPH) radical scavenging
activity
All synthesized compounds and BHT were screened for
free-radical-scavenging activity using the DPPH method.10
In brief, the compounds in methanol at different
concentrations (20e100 mg/mL) were added to each test
tube, and the volume was increased to 4 mL using
methanol. To perform this procedure, 3 mL of 0.004%
DPPH in methanol was added, and the mixtures were
incubated at room temperature in the dark for 30 min. The
DPPH-radical-scavenging activity was determined by
measuring the absorbance at 517 nm. The radical-scavenging
activity was calculated using the formula:
% of Radical-scavenging activity¼ ([(Acontrol  Atest)/Acontrol])
 100
Metal chelating activity
The chelating activity of the synthesized compounds
and the standard (EDTA) with ferrous ions was estimated
using a reported procedure.11 Briefly, 0.05 mL of 2 mM
FeCl2 was added to 3 mL of sample solution at different
concentrations (20e100 mg/mL). The reaction was
initiated by adding 0.2 mL of 5 mM ferrozine and
vigorously mixing and incubating at room temperature
for 10 min. The absorbance of the solution was
measured at 562 nm. The percentage of inhibition of the
ferrozine-Fe2þ complex formation was calculated using
the formula:
% of inhibition¼ ([(Acontrol  Atest)/Acontrol])  100
Results
Chemistry
The synthetic strategies to obtain the target compounds
3(aep) are shown in Scheme 1. In the present study, we
coupled heterocyclic aromatic carboxylic acids and fatty
acids with 5,6-dimethyl-1H-benzimidazol-2-amine to designa prodrug. Here, we experimentally observed the time to
complete the reaction and the product yield by catalysing the
reaction with HATU and EDC.HCl under different experi-
mental conditions (Table 1).
The catalytic observation of the reaction reveals that
the aliphatic acids react faster with HATU than
EDC.HCl. The HATU-catalysed reactions of halogen-
substituted acids and fatty acids completed in 3 h, but
the EDC.HCl-catalysed reaction completed in 6e7 h. In
the coupling of aromatic heterocyclic bioactive carboxylic
acids with compound 2, the HATU-catalysed reactions
were almost 2 times faster than the EDC.HCl-catalysed
reaction, and the yield was more economic. In the reac-
tion of simple and substituted aromatic carboxylic acids
with compound 2, because the acid was sterically crowded,
product formation slowed down in the EDC.HCl-
catalysed reaction, but there was no significant change in
time for product formation in the HATU-catalysed reac-
tion. Thus, HATU is an efficient catalyst in sterically
hindered couplings and provides a minimal level of
racemization.Pharmacology
In vitro antibacterial and antifungal activity
The antimicrobial and MIC results of the synthesized
compounds are tabulated inTable 2. The investigation reveals
that compound 3f had better activity against Pseudomonas
aeruginosa, Escherichia coli and Staphylococcus aureus, with
MIC values of 250, 250 and 500 mg/mL, respectively.
Compound 3g was highly active against P. aeruginosa and
moderately active against S. aureus, with an MIC value of
250 mg/mL. Compound 3h had maximum activity against
P. aeruginosa and moderate activity against S. aureus and
E. coli, with MIC values of 250, 500 and 500 mg/mL,
respectively. Compound 3j showed moderate to promising
activity against E. coli, S. aureus and P. aeruginosa, with
MIC values of 250e500 mg/mL. Compound 3l showed the
best zone of inhibition among all of the tested compounds
against all of the tested microorganisms, with an MIC value
of 250 mg/mL (see Table 3).
The antifungal activity results indicate that compound 3e
had a high zone of inhibition against Candida albicans and
demonstrated moderate inhibition against A. flavus and
Chrysosporium keratinophilum, with anMIC value of 250 mg/
mL. Compound 3h showed notably good activity, whereas 3j
showed a moderate zone of inhibition against all of the tested
fungal pathogens, with an MIC value of 250 mg/mL. Com-
pound 3l displayed significant, moderate and promising ac-
tivity against A. flavus, C. keratinophilum and C. albicans,
with an MIC value of 250 mg/mL.In silico molecular docking studies
The docking results reveal that compound 3j establishes
two hydrogen bonds with Val399 and Cys300 in the active
site of the target protein with minimum bond lengths (2.90
and 3.05 A). Compound 3l establishes two hydrogen bonds
with Val399 and Ala602 with bond lengths of 2.76 and
3.23 A and the highest affinity; hence, compound 3l dem-
onstrates the best dock conformation. In the in vitro studies,
compounds 3h and 3k also emerged as active antimicrobial
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Scheme: Synthesis of N-(5,6-dimethyl-1H-benzimidazol-2-yl)-substituted carboxamide derivatives.
Table 1: Time to complete the reaction and the yield.
Reaction catalysed
by HATU
Reaction catalysed
by EDC.HCl
Compound Time taken
for completion
of reaction
in hours
Yield
in %
Time taken
for completion
of reaction
in hours
Yield
in %
3a 4 78% 8 70%
3b 4 56% 8 66%
3c 4 58% 10 60%
3d 4 81% 10 75%
3e 3 96% 8 81%
3f 3 63% 8 58%
3g 5 75% 10 70%
3h 5 84% 10 69%
3i 5 81% 10 75%
3j 5 96% 10 75%
3k 6 94% 10 71%
3l 5 96% 10 68%
3m 3 91% 6 80%
3n 3 78% 6 54%
3o 3 80% 7 65%
3p 3 82% 6 52%
Synthesis of 2-amino-5,6-dimethyl-1H-benzimidazole derivatives422agents with one hydrogen bond with Leu346 and Val399,
respectively. Among the docked molecules, compounds 3k
and 3h show more hydrophobic interactions, whereas the
others show minimal hydrophobic interactions with the
tested protein.
Antioxidant activity
Free-radical-scavenging activity using the DPPH method
The DPPH-radical-scavenging activities of all of the
synthesized compounds are tabulated in Table 4.
Compounds 3(gej) were the most potent radical
scavengers, with IC50 values of 49.12  48, 48.15  54,
45.64  61 and 48.81  10 mg/mL, respectively.
Compounds 3(ken) showed significant radicle-scavenging
activities, with IC50 values of 89.46  53, 69.06  92,
86.24  39 and 87.49  32 mg/mL, respectively.
Iron-chelating ability
The ferrous-ion-chelating activity of the newly synthesized
compounds is shown in Table 4. Compound 3f showed
promising chelation activity. Compound 3h showed
Table 2: Antimicrobial activity data and MIC values of the synthesized compounds.
Zone of inhibition in mm (1000 mg/mL) Minimum inhibitory concentration (mg/mL)
Comp E. c. S.a. P.a. A.f. C.k. C.a. E. c. S.a. P.a. A.f. C.k. C.a.
3a 05  01 02  0.4 03  0.5 04  0.7 02  0.3 02  0.4 NT NT NT NT NT NT
3b 03  0.5 02  0.5 04  0.5 03  0.4 04  0.0 02  0.1 NT NT 1000 NT 1000 NT
3c 04  0.5 03  0.2 03  0.7 05  0.5 04  0.8 03  0.4 1000 NT NT 750 750 750
3d 03  0.6 02  0.9 02  0.8 01  0.5 03  0.4 02  0.2 NT NT NT NT NT NT
3e 11  0.5 12  0.1 11  0.4 13  0.8 10  0.7 19  0.5 500 500 500 250 250 250
3f 15  0.2 11  0.6 18  0.4 10  0.4 12  0.7 15  0.3 250 250 250 250 250 250
3g 09  0.1 17  0.5 19  0.5 15  0.7 13  0.5 10  0.1 500 250 250 250 750 750
3h 12  0.7 15  0.3 17  0.2 19  0.4 19  0.4 20  0.0 500 500 250 250 250 250
3i 10  0.1 10  0.5 09  0.5 11  0.8 10  0.7 09  0.4 750 750 750 750 750 750
3j 16  0.4 12  0.7 14  0.6 14  0.5 10  0.8 11  0.8 250 500 500 250 250 250
3k 10  0.6 08  0.7 09  0.6 09  0.8 12  0.4 11  0.3 750 750 750 750 750 750
3l 19  0.3 17  0.3 24  0.5 22  0.6 18  0.1 11  0.5 250 250 250 250 250 250
3m 05  0.8 06  0.5 07  0.6 06  0.5 08  0.2 02  0.6 750 750 750 750 750 750
3n 04  0.6 08  0.1 09  0.4 02  0.4 02  0.8 09  0.4 750 750 750 750 1000 750
3o 02  0.6 e e e e e NT NT NT NT NT NT
3p 01  0.1 e e e e e NT NT NT NT NT NT
Stnda 24  0.2 25  0.2 26  0.8 e e e 250 250 250 e e e
Stndb e e e 27  0.1 21  0.3 20  0.2 e e e 250 250 250
Each value is expressed as mean  SD of three replicates for the zone of inhibition, Stnda:Ciprofloxacin. Stndb:Fluconazole.
E.c- Escherichia coli, S.a- Staphylococcus aureus, P.a- Pseudomonas aeruginosa, A.f-Aspergillu sflavus, C.k-Chrysosporium keratinophilum,
C.a- Candida albicans. NT-Not tested.
Table 3: In silico docking study of the synthesized compounds.
Ligand Affinity
(kcal/mol)
H-Bonds H-Bond
length (A˚)
H-Bond with Hydrophobic interaction RMSd
3h 5.8 1 3.09 2VF5:Leu346:: 8:N3 Val605, Cys300, Ala404, Ser347 0.00
3i 8.0 0 e e Ala602 0.00
3j 10.1 2 2.90 2VF5:Val399::10:N3 Lys603, Gly301 0.00
3.05 2VF5:Cys300::10:N6
3k 8.4 1 2.89 2VF5:Val399::11:N3 Ala299,Gys300, Gly301,Leu346,Lys603 0.00
3l 8.4 2 2.76 2VF5:Val399::12:N3 Cys300, Lys603 0.00
3.23 2VF5:Ala602::12:O2
Ciprofloxacin 8.0 0 e e Cys300, Ser347, Gln348, Val399, Lys603 0.00
Fluconazole 7.3 5 2.69 2VF5:Lys603::fluconazole:O Cys300 0.00
2.82 2VF5:Lys603::fluconazole:O
3.04 2VF5:Val399::fluconazole:O
3.10 2VF5:Val399::fluconazole:N2
3.35 2VF5:Ala602::fluconazole:O
A.S. M. et al. 423significant chelating ability compared to the standard, with an
IC50 value of 49.00 65 mg/mL. Compounds 3g, 3i, 3j and 3k
showed significant activity, with IC50 values of 57.18  89,
77.09  77, 54.30  75 and 52.79  28 mg/mL, respectively.Discussion
We synthesized a series of 2-amino-5,6-dimethyl-1H-
benzimidazol derivatives that incorporated carboxylic acid
via an amide linkage using different catalytic methods. Our
results show the high coupling efficiencies of HATU with a
few undesired side reactions. In addition, many advantages,
such as solubility in water, cost effectiveness, eco-friendly
nature, easy handling, high reactivity and facile work-up
procedures, make HATU an efficient catalyst in organic
synthesis. However, EDC.HCl was proven to be vital for thesuccess of this synthetic methodology in terms of yield and
reaction time when aromatic carboxylic acid was sterically
unhindered.
The 1HNMR spectrum of compound 3a shows two sin-
glets at d 6.04 and 8.11 ppm because of the imidazole NH
proton and amide NH proton, respectively. The singlet at
d 2.31 ppm is assigned to two CH3 protons. Furthermore, the
13CNMR spectrum of compound 3a confirms the proposed
structure with the appearance of the signal at d 172.55 ppm,
representing the C]O group of amide, and another signal at
d20.26 ppm, which corresponds to two CH3 groups. The
mass spectrum of compound 3a has a molecular ion peak at
m/z 266.0[Mþ], which corresponds to the molecular mass of
the compound.
The structural activity relationship study of the synthe-
sized compounds shows that the compounds that have
electron-withdrawing substituents exhibit high zones of
Table 4: Antioxidant activity data of the synthesized
compounds.
Compound code IC50 mg/mL
DPPH scavenging Metal chelating
3a 224.92  82 166.68  15
3b 229.36  89 158.61  79
3c 217.49  80 193.04  65
3d 217.04  98 150.92  74
3e 120.50  78 108.81  44
3f 108.50  81 71.13  73
3g 49.12  48 57.18  89
3h 48.15  54 49.00  65
3i 45.64  61 77.09  77
3j 48.81  10 54.30  75
3k 89.46  53 52.79  28
3l 69.06  92 61.23  36
3m 86.24  39 66.19  38
3n 87.49  32 69.52  65
3 156.77  03 149.93  92
3p 183.26  29 159.27  21
std 40.40  93* 35.27  3.12**
*-BHT, **-EDTA.
Figure 1: 2D representation of the interaction of the synthesized m
respectively) with Glucosamine-6-phosphate synthase.
Synthesis of 2-amino-5,6-dimethyl-1H-benzimidazole derivatives424inhibition at lower MIC values. To support this observation,
the chloro and nitro groups at the para and ortho positions
are favourable for improved activity. Therefore, compounds
3e and 3f are potent antibacterial agents at low MIC values,
whereas the compounds that have no substituents have
notably lower zones of inhibition and high MIC values (3a).
Compounds 3o and 3p do not exhibit antimicrobial activity
possibly because of the steric hindrance in the molecules.
Compounds 3b, 3c and 3d exhibit negligible antimicrobial
activity against the tested pathogens, possibly because there
are electron-donating groups or bulkier substituents on the
benzene ring of the carboxylic acid used.
The molecular docking of ligand molecules 3h, 3i, 3j, 3k
and 3l with GlcN-6-P synthase shows that all of the tested
ligand molecules had encouraging binding energy, and the
compounds bonded with the amino acids in the active
pockets, as shown in Figures 1 and 2. Among the docked
molecules, compounds 3j and 3l demonstrated the best
docked conformations with the least binding affinity.
The significant antioxidant activity of compound 3f was
due to two strong electron-withdrawing nitro groups on the
benzene ring, making the molecule potentially active, which
may be attributed to the positively charged nitrogen atom of
the nitro group that stabilizes the radicals. The antioxidant
activity of compound 3g may be attributed to theolecules 3j, 3l, ciprofloxacin and fluconazole (A, B, C and D,
Figure 2: 3D representation of the interaction of the synthesized molecules 3j, 3l, ciprofloxacin and fluconazole (A, B, C and D,
respectively) with Glucosamine-6-phosphate synthase.
A.S. M. et al. 425participation of the NH of the triazole ring of the benzimid-
azole ring. The activity of compound 3h may be attributed to
the benzimadazole ring of the 1,2-oxazole ring. The potential
activity of compound 31 is due to the combination of the
benzofuran ring with benzimidazole. Compounds 3m and 3n
showedpromising scavenging activity because of the electron-
withdrawing group on the side chain. The activity of com-
pounds 3n and 3p decreases because of their steric hindrance.Conclusion
Our study reveals that the incorporation of a heterocyclic
ring, such as thiazole, oxazole, pyridine, benzotriazole, and
benzofuran, and open-chain counterparts at the second posi-
tion of the benzimidazole ring yields more potent biologically
active compounds. The antimicrobial activity results show
that the benzimidazole nucleus that is coupled with another
bioactive heterocyclic aromatic moiety has enhanced activity.
The antioxidant results show that electron-withdrawing
groups enhance activity compared to compounds that have
electron-donating groups, whereas the derivatives that have a
long aliphatic chain have minimal activity.Conflict of interests
The authors declare no competing interests relating to this
article.Authors’ contribution
ASM conceived and designed the study, conducted
research, wrote initial and final draft of the article. YDB is
responsible for the critical revision of the article and final
approval of the version to be published. KR analyzed and
interpreted the spectral data. ST carried out the biological
studies and computational work. CA provided research
materials, collected literature and organized the data and VB
provided logistic support. All authors have critically
reviewed and approved the final draft and are responsible for
the content and similarity index of the manuscript.Acknowledgements
The authors are thankful to the Department of Industrial
Chemistry, Kuvempu University, Shankaraghatta, for
providing the laboratory facilities.References1. Kamalpriya G, Yogita B, Gulshan B, Goel RK. Design, syn-
thesis, and PASS-assisted evaluation of novel 2-substituted
benzimidazole derivatives as potent anthelmintics. Med Chem
Res 2014; 23: 2690e2697.
2. Balasubramanian N, Deepika S, Pradeep K. Benzimidazole: a
medicinally important heterocyclic moiety. Med Chem Res
2012; 21: 269e273.
Synthesis of 2-amino-5,6-dimethyl-1H-benzimidazole derivatives4263. Desai MC, Stephens Stramiello LM. Polymer bound EDC (P-
EDC): a convenient reagent for formation of an amide bond.
Tetrahedron Lett 1993; 34: 7685e7688.
4. Zhang M, Vedantham P, Flynn DL, Hanson PR. High-
load, soluble oligomericcarbodiimide: synthesis and appli-
cation in coupling reactions. J Org Chem 2004; 69(24):
8340e8344.
5. Chinchilla R, David JD, Carmen N, Jose M. Soriano Polymer-
bound TBTU as a new solid-supported reagent for peptide
synthesis. Tetrahedron Lett 2000; 41: 463e466.
6. Filip SV, Lejeune V, Vors JP, Martinez J, Cavelier F. Peptide
bond formation using polymer-bound BOP. Eur J Org Chem
2004; 9: 1936e1939.
7. Yogita B, Maninder K, Om S. Benzimidazole eibuprofen/
mesalamine conjugates: potential candidates for multifactorial
diseases. Eur J Med Chem 2015; 89: 671e672.
8. Sheelavanth S, Yadav DB, Sundar SM. Synthesis, antioxidant,
and antibacterial studies of phenolic esters and amides of 2-(1-
benzofuran-2-yl) quinoline-4-carboxylic acid. Med Chem Res
2013; 22: 1163e1171.9. MouilleronS,Badet-DenisotMA,Golinelli-PimpaneauB.Ordering
of C-terminal loop and glutaminase domains of glucosamine-6-
phosphate synthase promotes sugar ring opening and formation of
the ammonia channel. JMol Biol 2008; 377: 1174e1175.
10. Kenchappa R, Bodke YD, Peethambar SK, Sandeep T,
Venkatesh KB. Synthesis of b-amino carbonyl derivatives of
coumarin and benzofuran and evaluation of their biological
activity. Med Chem Res 2013; 22: 4787e4797.
11. Nevcihan G, Cengiz S, Bektas T, Halil SM. Evaluation of
antioxidant activities of 3 edible mushrooms; Ramariaflava,
Rhizopoganroseolus and Russuladelica. Food Sci Biotech 2010;
19(3): 691e696.How to cite this article: M. AS, Bodke YD, R. K, Telkar S,
A. C, B.M. V. Catalytic assemble of 2-amino-5,6-
dimethyl-1H-benzimidazole with carboxylic acids and
evaluation of their antimicrobial and antioxidant activ-
ities. J Taibah Univ Med Sc 2016;11(5):418e426.
